Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial
Authors
Morris, S.Scarisbrick, J.
Arumainathan, A.
Bates, A.
Cheadle, E.
Collins, G.
Cowan, R.
El-Mehidi, N.
O'Rourke, N.
Osbourne, W.
Pawade, J.
Robinson, S.
Tyson, C.
Ward, J.
Whittaker, S.
Wilson, W.
Illidge, Timothy
Affiliation
The Christie NHS, Oncology, Manchester, United KingdomIssue Date
2024
Metadata
Show full item recordCitation
Morris S, Scarisbrick J, Arumainathan A, Bates A, Cheadle E, Collins G, et al. Efficacy and safety of pembrolizumab and radiotherapy in relapsed/ refractory cutaneous T cell lymphoma: results of the PORT trial. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S22-S3. PubMed PMID: WOS:001330761900048. English.Journal
European Journal of CancerDOI
10.1016/j.ejca.2024.114386Additional Links
https://dx.doi.org/10.1016/j.ejca.2024.114386Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.114386